Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Hubei
Clinical trial register · China

Clinical Trials in Hubei, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19212 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:17 UTC
19212
Studies in scope
all four open statuses
11805
Recruiting now
open to new participants
2029
Lead sponsors
across recruiting studies
Top sites
Beijing 5582 Shanghai 3880 Guangzhou 3354 Hangzhou 1824 Wuhan 1342
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5582 Shanghai3880 Guangzhou3354 Hangzhou1824 Wuhan1342
All 625 locations
Target enrolment
to

Trials with a site in Hubei

25 of 19212 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
UCARsgen Biotech Limited
Phase 1/2
68
Shanghai, Hubei
2026-09-13
Recruiting
Phase III Clinical Trial of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
NCT07860216Assessing the Effectiveness of Vaccines in Preventing Adult RSV-caused Lower Respiratory Tract Disease (LRTD)
Beijing BeneWill Technology Development Co., Ltd
Phase 3
25,000
GuiZhou, Hebei, HuBei, HuNan, Shandong, Shanxi, Baoshan
2026-08-21
Recruiting
AstraZeneca
Observational
10
Beijing, Hubei
2026-08-18
Not yet open
Sinovac Biotech Co., Ltd
Phase 3
6,000
Hefei, Fujian, Henan, Hubei, Sichuan
2026-05
Recruiting
Daishi Tian
Early Phase 1
9
Hubei
2026-03-09
Recruiting
Shenzhen Majory Biotechnology Co., Ltd.
Phase 1/2
42
Beijing, Hubei, Hunan
2026-01-29
Recruiting
ePRO in Advanced Lung Cancer: Emotional Distress, Symptom Burden, Brain Metastasis
NCT07912190Lung Cancer, Brain Metastasis, Patient Reported Outcome
Qian Chu
Observational
200
Hubei
2026-01-04
Recruiting
Beijing Continent Pharmaceutical Co, Ltd.
Phase 1
56
Hubei
2025-12-25
Not yet open
Tongji Hospital
Not applicable
300
Hubei
2025-10-01
Recruiting
DualityBio Inc.
Phase 2
750
Beijing, Dongguan, Henan, Xinxiang, Hubei, Wuhan, Changsha, Xuzhou
2025-07-18
Recruiting
Preliminary Human Trials of F230 Tablets
NCT06899815Pulmonary Hypertension
Beijing Continent Pharmaceutical Co, Ltd.
Phase 1
136
Hubei
2025-05-15
Recruiting
A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
NCT06820268B-cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1
168
Beijing, Guangdong, Hebei, Hubei
2025-01-14
Recruiting
Sinovac Biotech Co., Ltd
Phase 3
8,000
Hefei, Fujian, Guangdong, Hubei
2024-12-13
Recruiting
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
NCT06750419Clear Cell Renal Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
82
Beijing, Hangzhou, Hubei, Shanghai, Suzhou, Tianjin, Wuxi, Zhejiang
2024-11-06
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
45
Hubei
2024-10-16
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
29
Wuhan, Hubei
2024-07-19
Recruiting
Hospital of Stomatology, Wuhan University
Phase 2
35
Hubei
2023-08-19
Not yet open
Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma
NCT05909098NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory
Xiangyang No.1 People's Hospital
Phase 1/2
33
Hubei
2023-07-01
Recruiting
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Genmab
Phase 1/2
952
Beijing, Fujian, Guangdong, Henan, Hubei, Shanxi, Shengyang, Tianjin
2022-12-07
By invitation
Abbisko Therapeutics Co, Ltd
Phase 2
118
Hubei
2021-12-30
Active, closed
Haihe Biopharma Co., Ltd.
Phase 2
93
Beijing, Chongqing, Guangdong, Haikou, Hainan, Hangzhou, Harbin, Hubei
2021-10-11
Active, closed
AstraZeneca
Phase 3
110
Beijing, Chongqing, Guangzhou, Guizhou, Henan, Hubei, Hunan, Jilin City
2021-06-24
Active, closed
Daiichi Sankyo
Phase 3
605
Beijing, Changsha, Hangzhou, Hangzou, Heilongjiang, Henan, Hubei, Nanjing
2020-12-21
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 2
393
Beijing, Changchun, Chongqing, Guangdong, Guangzhou, Harbin, Hubei, Jiangsu
2019-03-15
Active, closed
Astellas Pharma Global Development, Inc.
Phase 2
900
Hubei, Hunan, Nanjing
2016-12-22
Rows per page Showing 1–25 of 25
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/city/hubei

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,212 studies in total at the last sync on 10 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 25 of those studies with a site in Hubei.

How many clinical trials are recruiting in Hubei?

16 of the 25 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:17 UTC sync. A further 3 have not yet opened recruitment, 5 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hubei), 25 studies
PhaseStudiesRecruitingShare
Phase 28432%
Phase 36324%
Phase 1/24316%
Phase 13312%
Observational228%
Early Phase 1114%
Not applicable104%

Most active sponsors

Lead sponsors with the most studies (Hubei)
Lead sponsorStudiesRecruiting
Astellas Pharma Global Development, Inc.20
AstraZeneca21
Beijing Continent Pharmaceutical Co, Ltd.22
Sinovac Biotech Co., Ltd21
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology22
Abbisko Therapeutics Co, Ltd10
Beijing BeneWill Technology Development Co., Ltd11
Daiichi Sankyo10
Daishi Tian11
DualityBio Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.